Showing posts from July, 2019

Exploring Experimental Hematology: CD123 CAR T cells for the treatment of myelodysplastic syndrome

In this issue of Simply Blood, Christophe Lancrin is exploring Experimental Hematology by highlighting and deconstructing one of his favorite manuscripts from the ISEH society journal: "CD123 CAR T cells for the treatment of myelodysplastic syndrome."
The power to utilize the adaptive immune system to kill cancer cells has long been recognized to have tremendous therapeutic potential but for many years this remained only an elusive dream. However, over the past few decades, tremendous progress has been made along this front. One notable (and Nobel worthy!) breakthrough was the understanding of immune checkpoints. This helped in the design of effective cancer immunotherapies by removing the “brakes” called PD1 and CTLA4 that restrict the immune response of T lymphocytes against cancer cells. Now, antibodies specific to these molecules have proven to be powerful weapons against cancers previously considered untreatable such as metastatic melanoma.

Chimeric antigen receptor T …

ISEH July 2019 – Message from the President: Bertie Gottgens

Dear ISEH Friends and Colleagues,

This is my final president’s message before I will be stepping down at the end of the ISEH Annual Meeting in August in Brisbane. It has been a real privilege to work on your behalf, with invaluable support from enthusiastic volunteers from right across the globe as well as our dedicated team at SmithBucklin in Chicago. We are fortunate to see exciting breakthroughs in our field on an almost weekly basis, where ground-breaking discoveries in basic research go hand-in-hand with the development of exciting new therapies. Such breakthroughs critically depend on a vibrant research community, and I believe that we can all be proud of the important contributions that the ISEH has made over the last nearly 50 years to foster exactly this.

I am happy to provide you all with an update on the developing partnership between ISEH and the European Hematology Association (EHA). Over 12,000 delegates attended the annual EHA meeting in June in Amsterdam, which in…